Occupational transdermal poisoning with synthetic cannabinoid cumyl-PINACA

  title={Occupational transdermal poisoning with synthetic cannabinoid cumyl-PINACA},
  author={Mojca Dobaja and Damjan Grenc and Gordana Ko{\vz}elj and Miran Brvar},
  journal={Clinical Toxicology},
  pages={193 - 195}
Abstract Context: Synthetic cannabinoids are getting more popular among young people and illicit manufacturers. We report a case series of occupational transdermal poisoning with synthetic cannabinoids. Case details: Three customs inspectors got in contact with a sticky substance with their fingertips because they were not wearing protection gloves and the delivered package was damaged. Despite washing their hands with water, signs of synthetic cannabinoids intoxication started occurring half… 
Synthetic Cannabinoid and Mitragynine Exposure of Law Enforcement Agents During the Raid of an Illegal Laboratory — Nevada, 2014
To protect agents from SC exposures, NIOSH recommended that the agency require agents to wear a minimum level of PPE and undergo training in PPE in handling and storing of contaminated evidence from SC laboratory raids and evidence processing.
CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist
It is reported here that CUMYL-4CN-BINACA is a potent CB1 receptor agonist that produces pro-convulsant effects in mice at a lower dose than reported for any SCRA to date, and may underpin the toxicity associated with this compound in humans.
Cannabimimetic activities of cumyl carboxamide-type synthetic cannabinoids
This study synthesized seven cumyl carboxamide-type synthetic cannabinoids and evaluated their activities as CB1 and CB2 receptor agonists and showed the analytical characterization of these compounds using gas chromatography–electron ionization-mass spectrometry.
Rapid Simultaneous Determination of 11 Synthetic Cannabinoids in Urine by Liquid Chromatography-Triple Quadrupole Mass Spectrometry
Synthetic cannabinoids are a series of synthetic substances that mimic the effects of natural cannabinoids and produce a much stronger toxicity than natural cannabinoids, which have become the most
Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures
People who smoke carboxamide-type synthetic cannabinoids are likely to be exposed to a range of potentially toxic thermal degradants, including cyanide, which could have significant health impacts in human users.
Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures.
The origins of NPS are traced, the work of the EMCDDA is discussed, and a growing number of highly potent substances that can pose a high risk of life-threatening poisoning to users and can cause explosive outbreaks are monitored.
In vitro metabolism of the synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA.
Several constitutional isomers containing either an indazole or azaindole core structure were detected, which should be differentiated by retention time rather than by their mass spectra alone and should not be used as marker for the intake of a particular parent compound.
Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues.
Hypothermia was reversed by pretreatment with a CB1, but not CB2, antagonist, confirming that cumyl-derived SCs are cannabimimetic in vivo.


Spicing things up: synthetic cannabinoids
There is an urgent need for better research on the effects of synthetic cannabinoids to help clinicians manage adverse events and to better understand cannabinoid pharmacology in humans.
K2—Not the Spice of Life; Synthetic Cannabinoids and ST Elevation Myocardial Infarction: A Case Report
Urine drug immunoassays may be unreliable and in this case did not detect synthetic cannabinoids, and Cardiac catheterization revealed normal coronary arteries, no wall motion abnormalities, and normal systolic function.
A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment
To identify systematically the scientific reports of adverse events associated with the consumption of SCs in the medical literature and poison centre data, this work searched online databases and manually searched reference lists up to December 2014 to identify eligible studies.
Top 10 Facts You Need to Know About Synthetic Cannabinoids: Not So Nice Spice.
Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers
The results of this study indicated that CBD could be successfully delivered through the IN and transdermal routes, and the achievement of a significant steady-state plasma concentration indicates that CBD is useful for chronic pain treatment through this route of administration.
Transdermal permeation of WIN 55,212-2 and CP 55,940 in human skin in vitro.
Transdermal Delivery of the Synthetic Cannabinoid WIN 55,212-2: In Vitro/in Vivo Correlation
The observed in vivo results from the Hill Top Chambers and TTS patches in the guinea pigs were in good agreement with the predicted plasma concentrations from the in vitro data, indicating that the percutaneous absorption of the synthetic cannabinoid WIN 55,212-2 in vitro and in vivo was satisfactory.
Crystal Structure of the Human Cannabinoid Receptor CB1
Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.
Synthetic cannabinoid designer drugs based on indole and indazole scaffolds and featuring l-valinamide or l-tert-leucinamide side chains and several analogues are synthesized and characterized, indicating that these SCs are cannabimimetic in vivo, consistent with anecdotal reports of psychoactivity in humans.
Clinical toxicity of synthetic cannabinoid receptor agonist use
  • Clin Toxicol
  • 2015